IL161138A0 - Treatment of hepatitis b virus infection with human monoclonal antibodies - Google Patents

Treatment of hepatitis b virus infection with human monoclonal antibodies

Info

Publication number
IL161138A0
IL161138A0 IL16113801A IL16113801A IL161138A0 IL 161138 A0 IL161138 A0 IL 161138A0 IL 16113801 A IL16113801 A IL 16113801A IL 16113801 A IL16113801 A IL 16113801A IL 161138 A0 IL161138 A0 IL 161138A0
Authority
IL
Israel
Prior art keywords
hepatitis
treatment
monoclonal antibodies
virus infection
human monoclonal
Prior art date
Application number
IL16113801A
Original Assignee
Xtl Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xtl Biopharmaceuticals Ltd filed Critical Xtl Biopharmaceuticals Ltd
Publication of IL161138A0 publication Critical patent/IL161138A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16113801A 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies IL161138A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2001/000927 WO2003028722A1 (en) 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies

Publications (1)

Publication Number Publication Date
IL161138A0 true IL161138A0 (en) 2004-08-31

Family

ID=11043099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16113801A IL161138A0 (en) 2001-10-04 2001-10-04 Treatment of hepatitis b virus infection with human monoclonal antibodies

Country Status (7)

Country Link
EP (1) EP1432418A1 (en)
JP (1) JP2005505582A (en)
KR (1) KR20040048935A (en)
CN (1) CN1558763A (en)
CA (1) CA2462427A1 (en)
IL (1) IL161138A0 (en)
WO (1) WO2003028722A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9292111B2 (en) 1998-01-26 2016-03-22 Apple Inc. Gesturing with a multipoint sensing device
US8479122B2 (en) 2004-07-30 2013-07-02 Apple Inc. Gestures for touch sensitive input devices
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
KR101280273B1 (en) 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Stabilized anti-hepatitis B (HBV) antibody formulations
KR20090056537A (en) * 2007-11-30 2009-06-03 주식회사 녹십자 Composition comprising a human antibody capable of neutralizing hepatitis b virus for preventing or treating hepatitis b virus infection
CN102757492A (en) * 2011-04-26 2012-10-31 中国人民解放军第二军医大学 Holistic hepatitis B surface protein monoclonal antibodies and application thereof to preparation of medicines for preventing HBV (hepatitis B virus) infection
KR101771309B1 (en) * 2015-07-24 2017-08-24 재단법인 목암생명과학연구소 PHARMACEUTICAL COMPOSITION FOR PREVENTING cccDNA FORMATION OF HEPATITIS B VIRUS
CN105001325A (en) * 2015-07-31 2015-10-28 北京泰诺迪生物科技有限公司 Total-humanized anti-hepatitis B virus neutralizing antibody and preparing method and application thereof
WO2017114812A1 (en) * 2015-12-29 2017-07-06 F. Hoffmann-La Roche Ag Combination therapy of an hbsag inhibitor and an interferon
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
EP0893124A1 (en) * 1997-07-24 1999-01-27 Roche Diagnostics GmbH Pharmaceutical combination preparations comprising human monoclonal antibodies for the treatment of chronic hepatitis B and a virostatic substance

Also Published As

Publication number Publication date
KR20040048935A (en) 2004-06-10
WO2003028722A1 (en) 2003-04-10
CN1558763A (en) 2004-12-29
EP1432418A1 (en) 2004-06-30
CA2462427A1 (en) 2003-04-10
JP2005505582A (en) 2005-02-24

Similar Documents

Publication Publication Date Title
PL399548A1 (en) Methods of administering anti-TNFα antibodies
SI1404347T1 (en) 4'-substituded nucleosides for the treatment of diseases mediated by the hepatitis c virus
ZA200107822B (en) Inhibition of viral infection using monovalent antigen-binding proteins.
EE05442B1 (en) A low dose entecavir pharmaceutical composition for the treatment of hepatitis B virus infection and a method for its preparation
AU2002349727A1 (en) Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
EP1765330A4 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
EP1446121A4 (en) Diindolylmethane for the treatment of hpv infection
AU2158000A (en) Treatment of hepatitis c virus infections with interleukin-10
EP1497654A4 (en) Immunoglobulin e vaccines and methods of use thereof
HK1062579A1 (en) A fusion protein for treatment of hepatitis b virus and its use thereof
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
IL161138A0 (en) Treatment of hepatitis b virus infection with human monoclonal antibodies
AU2002246545A1 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2003247841A8 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
PL356640A1 (en) Treatment of viral infections using levovirintm
NO20041855L (en) Procedure for the treatment of hepatitis C virus infection in the treatment of malignant patients
AP2002002432A0 (en) Treatment of viral infections
NO20041685L (en) Procedure for the treatment of hepatitis C virus infection in patients with non-treatment response
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
AU2003287216A8 (en) Gb virus c and methods of treating viral infections
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2003299493A8 (en) Compositions and methods for the treatment of hepatitis c virus infection
AU7716900A (en) Hcv e2 protein binding agents for treatment of hepatitis c virus infection
AU2001282560A1 (en) Methods of infection with hepatitis c virus